Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Completed
National Cancer Institute (NCI)
Phase 2
2005-01-01
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop
growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating
factors such as filgrastim or pegfilgrastim may increase the number of immune cells found in
bone marrow or peripheral blood and may help a person's immune system recover from the side
effects of chemotherapy. This phase II trial is studying how well combination chemotherapy
plus filgrastim or pegfilgrastim works in treating patients with recurrent or persistent
cancer of the uterus.
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Completed
Gynecologic Oncology Group
Phase 2
2005-01-01
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop
growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating
factors such as filgrastim or pegfilgrastim may increase the number of immune cells found in
bone marrow or peripheral blood and may help a person's immune system recover from the side
effects of chemotherapy. This phase II trial is studying how well combination chemotherapy
plus filgrastim or pegfilgrastim works in treating patients with recurrent or persistent
cancer of the uterus.
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Completed
National Cancer Institute (NCI)
Phase 3
2003-08-25
This randomized phase III trial compares how well two different combination chemotherapy
regimens (doxorubicin hydrochloride, cisplatin, and paclitaxel versus carboplatin and
paclitaxel) work in treating patients with endometrial cancer that is stage III-IV or has
come back (recurrent). Drugs used in chemotherapy such as doxorubicin hydrochloride,
cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. It is not yet known which combination chemotherapy regimen is more effective in
treating endometrial cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
